Mostrar el registro sencillo del ítem

dc.contributor.authorGonzalez-Lopez, Esther 
dc.contributor.authorMcPhail, Ellen D
dc.contributor.authorSalas-Anton, Clara
dc.contributor.authorDominguez, Fernando 
dc.contributor.authorGertz, Morie A
dc.contributor.authorDispenzieri, Angela
dc.contributor.authorDasari, Surendra
dc.contributor.authorMilani, Paolo
dc.contributor.authorVerga, Laura
dc.contributor.authorGrogan, Martha
dc.contributor.authorPalladini, Giovanni
dc.contributor.authorGarcia-Pavia, Pablo 
dc.date.accessioned2024-07-04T10:29:02Z
dc.date.available2024-07-04T10:29:02Z
dc.date.issued2024-03-19
dc.identifier.citationJ Am Coll Cardiol. 2024 Mar 19;83(11):1085-1099.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20054
dc.description.abstractCardiac amyloidosis is increasingly recognized as a treatable form of heart failure. Highly effective specific therapies have recently become available for the 2 most frequent forms of cardiac amyloidosis: immunoglobulin light chain amyloidosis and transthyretin (ATTR) amyloidosis. Nevertheless, initiation of specific therapies requires recognition of cardiac amyloidosis and appropriate characterization of the amyloid type. Although noninvasive diagnosis is possible for ATTR cardiac amyloidosis, histological demonstration and typing of amyloid deposits is still required for a substantial number of patients with ATTR and in all patients with light chain amyloidosis and other rarer forms of cardiac amyloidosis. Amyloid histological typing can be performed using different techniques: mass spectrometry, immunohistochemistry, and immunoelectron microscopy. This review describes which patients require histological confirmation of cardiac amyloidosis along with when and how to type amyloid deposits in histologic specimens. Furthermore, it covers the characteristics and limitations of the different typing methods that are available in clinical practice.es_ES
dc.description.sponsorshipThis study has been partially supported by Instituto de Salud Carlos III through the projects “PI18/0765 and PI20/01379” (cofunded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). The Centro Nacional de Investigaciones Cardiovasculares is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovación, the ProCentro Nacional de Investigaciones Cardiovasculares Foundation, and the Severo Ochoa grant (CEX2020-001041-S). This work was also supported by grants from the Italian Ministry of Health (Ricerca Finalizzata, grant #GR-2018-12368387), the Italian Ministry of Research and Education (PRIN 20207XLJB2), Cancer Research UK 4013 (C355/A26819), Fundación Científica Asociación Española Contra el Cáncer, and AIRC under the Accelerator Award Program. The authors have reported that they have no relationships relevant to the content of this paper to disclose.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAmyloidosis es_ES
dc.subject.meshHeart Failure es_ES
dc.subject.meshAmyloid Neuropathies, Familial es_ES
dc.subject.meshCardiomyopathies es_ES
dc.subject.meshHumans es_ES
dc.subject.meshPlaque, Amyloides_ES
dc.subject.meshAmyloid es_ES
dc.subject.meshImmunohistochemistry es_ES
dc.subject.meshAmyloidogenic Proteins es_ES
dc.subject.meshPrealbumin es_ES
dc.titleHistological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week.es_ES
dc.typereview articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID38479957es_ES
dc.format.volume83es_ES
dc.format.number11es_ES
dc.format.page1085es_ES
dc.identifier.doi10.1016/j.jacc.2024.01.010es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1558-3597es_ES
dc.relation.publisherversion10.1016/j.jacc.2024.01.010es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Miocardiopatías Hereditariases_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI18/0765es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI20/01379es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional